CONSOLIDATED STATEMENTS OF LOSS (USD $) In Millions, except Per Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Revenues
Product sales	$ 1,851.1	$ 1,038.9
Other revenues	35.1	29.5
Total revenues	1,886.2	1,068.4
Expenses
Cost of goods sold (exclusive of amortization and impairments of finite-lived intangible assets shown separately below)	504.1	284.9
Cost of alliance and service revenues	14.3	15.4
Selling, general and administrative	482.0	241.9
Research and development	61.3	23.8
Amortization and impairments of finite-lived intangible assets (see Note 7)	355.2	326.2
Restructuring, integration and other costs	133.6	49.0
In-process research and development impairments and other charges	12.0	0
Acquisition-related costs	1.5	7.9
Acquisition-related contingent consideration	8.9	(2.2)
Other (income) expense	(43.3)	4.5
Total expenses	1,529.6	951.4
Operating income	356.6	117.0
Interest income	1.8	1.6
Interest expense	(246.5)	(155.3)
Loss on extinguishment of debt	(93.7)	(21.4)
Foreign exchange and other	(13.4)	1.4
Gain on investments, net	0	1.9
Income (loss) before provision for (recovery of) income taxes	4.8	(54.8)
Provision for (recovery of) income taxes	25.1	(27.3)
Net loss	(20.3)	(27.5)
Less: Net income attributable to noncontrolling interest	2.3	0
Net loss attributable to Valeant Pharmaceuticals International, Inc.	$ (22.6)	$ (27.5)
Loss per share attributable to Valeant Pharmaceuticals International, Inc.:
Basic and diluted (in dollars per share)	$ (0.07)	$ (0.09)
Weighted-average common shares
Basic and diluted (in shares)	334.9	305.8